Quantcast

Latest PEGylation Stories

2011-09-14 11:15:38

Press release from PLoS Medicine In this week's PLoS Medicine, David Booth of the University of Sydney, Australia and colleagues show that genotyping hepatitis C patients for the IL28B, HLA-C and KIR genes substantially improves doctors' ability to predict whether or not patients will respond to antiviral treatment. The results of the study suggest that an interaction between IL28B, HLA-C and KIRs provides a mechanism for hepatitis C viral control and highlight new insights into how the...

2011-08-02 15:05:00

SAN DIEGO, Aug. 2, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will report second quarter 2011 financial results on Monday, August 8, 2011, after the U.S. financial markets close. Anadys will hold a conference call and webcast on Monday, August 8, 2011, at 5:00 p.m. Eastern Daylight Time to discuss its second quarter 2011 financial results and highlights. A live webcast of the call will be available online at www.anadyspharma.com. A telephone...

2011-07-28 07:00:00

SAN DIEGO, July 28, 2011 /PRNewswire/ -- Polaris Group (Polaris) today announced that it has dosed the first patient in a pivotal Phase 3 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in hepatocellular carcinoma (HCC) patients. Over 600 patients who have failed prior systemic therapy will be enrolled in the randomized, double-blind, placebo-controlled study at sites in China, Taiwan, the United States, Italy and the U.K.. Patients will...

2011-07-11 06:30:00

NES-ZIONA, Israel, July 11, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for a patent application covering the company's CTP platform, which has the potential to extend the duration of activity of virtually all therapeutic proteins. The allowed claims cover CTP-modified compositions of a wide array of classes of therapeutic proteins, including hormones, high affinity...

2011-06-27 08:00:00

-- Sigma-Tau Pharmaceuticals, Inc. Announces Co-Pay Program for Oncaspar® (pegaspargase) -- GAITHERSBURG, Md., June 27, 2011 /PRNewswire-USNewswire/ -- Today, Sigma-Tau Pharmaceuticals, Inc. announced a vital new service for people with Acute Lymphoblastic Leukemia (ALL). The Sigma-Tau Outreach Service (S.O.S.) will now refund eligible patients 100 percent of any co-pay associated with their prescription for Oncaspar®. For more information on...

2011-06-13 06:30:00

NES-ZIONA, Israel, June 13, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today announced that the U.S. Patent and Trademark Office (PTO) has allowed a new patent for the company's veterinary version of its long-acting CTP-enhanced non-human growth hormone (NhGH-CTP). The patent covers the composition of PROLOR's proprietary pharmaceutical non-human growth hormone as well as certain associated methods of use for veterinary applications. "This new patent covering...

2011-06-06 06:00:00

NES-ZIONA, Israel, June 6, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH) today reported positive results from a comparative animal study of its long-acting anti-obesity drug candidate oxyntomodulin (OXY-RPEG). The study measured the potential therapeutic effect of OXY-RPEG injected once or twice weekly as measured by weight loss and reduction in food intake compared with oxyntomodulin injected twice daily. It was conducted using a state-of-the-art animal model specifically...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related